Clinical observation of venetoclax combined with homoharringtonine and cytarabine in the treatment of acute myeloid leukemia
- VernacularTitle:维奈克拉联合高三尖杉酯碱和阿糖胞苷治疗急性髓系白血病的临床观察
- Author:
Ling ZHOU
1
;
Qiuyuan PENG
1
;
Pan ZHAO
1
;
Jin WEI
1
;
Xiaojing LIN
1
;
Xingli ZOU
1
;
Wenfeng LUO
1
;
Jing WANG
1
;
Kunying XIE
1
;
Xianglong LI
1
;
Yang LIU
1
;
Xun NI
1
Author Information
1. Dept. of Hematology，the Affiliated Hospital of North Sichuan Medical College，Sichuan Nanchong 637000，China
- Publication Type:Journal Article
- Keywords:
acute myeloid leukemia;
venetoclax
- From:
China Pharmacy
2024;35(14):1743-1747
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To observe the short-term efficacy and safety of venetoclax combined with homoharringtonine and cytarabine in the treatment of acute myeloid leukemia （AML）. METHODS The data of 40 newly diagnosed AML patients admitted to our hospital from October 2022 to November 2023 were retrospectively collected and divided into observation group and control group according to treatment plan， with 20 cases in each group. The patients in the control group were given Daunorubicin hydrochloride for injection+Cytarabine for injection， and the patients in the observation group were given Venetoclax tablets+ Homoharringtonine injection+Cytarabine for injection. The patients in both groups were given relevant medicine， with 28 days as one cycle. The short-term efficacy， negative rate of minimal residual disease （MRD）， duration of granulocyte deficiency， duration of platelet （PLT） ＜20×109 L－1， transfusion volume of suspended red blood cells and platelet， and the occurrence of adverse drug reactions were evaluated in both groups after 1 cycle of induction chemotherapy. RESULTS The complete remission or complete remission with incomplete hematologic recovery （CR/CRi） rate in the observation group was significantly higher than control group （P＜0.05）， and the negative rate of MRD in the observation group was also significantly higher than control group （P＜0.05）. However， in low-， medium- and high-risk patients， there was no statistical significance in CR/CRi rates between the two groups （P＞0.05）. There were no significant differences in the duration of agranulocytosis， the duration of PLT ＜20×109 L－1， the amount of suspended red blood cell transfusion， the amount of platelet transfusion， the incidence of hematologic toxicity and the incidence of non-hematologic toxicity between 2 groups （P＞0.05）. CONCLUSIONS Venetoclax combined with homoharringtonine and cytarabine show good short-term efficacy and safety in the treatment of AML.
